{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T13:30:16Z","timestamp":1773840616263,"version":"3.50.1"},"reference-count":16,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2020,5,3]],"date-time":"2020-05-03T00:00:00Z","timestamp":1588464000000},"content-version":"unspecified","delay-in-days":2,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"FB Ireland\/HRB","award":["MRCG\/2011\/12"],"award-info":[{"award-number":["MRCG\/2011\/12"]}]},{"DOI":"10.13039\/501100001665","name":"Agence Nationale de la Recherche","doi-asserted-by":"publisher","award":["ANR-12-BSV1-0019-02"],"award-info":[{"award-number":["ANR-12-BSV1-0019-02"]}],"id":[{"id":"10.13039\/501100001665","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000030","name":"Institute of Genetics","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/501100000030","id-type":"DOI","asserted-by":"publisher"}]},{"name":"FB Canada","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}]},{"DOI":"10.13039\/501100001602","name":"Science Foundation Ireland","doi-asserted-by":"publisher","award":["16\/IA\/4452"],"award-info":[{"award-number":["16\/IA\/4452"]}],"id":[{"id":"10.13039\/501100001602","id-type":"DOI","asserted-by":"publisher"}]},{"name":"NIH","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open Ophth"],"accepted":{"date-parts":[[2020,4,2]]},"published-print":{"date-parts":[[2020,5]]},"abstract":"<jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>No therapeutic interventions are currently available for autosomal dominant retinitis pigmentosa (adRP). An RPE65 Asp477Gly transition associates with late-onset adRP, reduced RPE65 enzymatic activity being one feature associated with this dominant variant. Our objective: to assess whether in a proof-of-concept study, oral synthetic 9 <jats:italic>cis<\/jats:italic>-retinyl acetate therapy improves vision in such advanced disease.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods and analysis<\/jats:title>\n                  <jats:p>A phase 1b proof-of-concept clinical trial was conducted involving five patients with advanced disease, aged 41\u201368 years. Goldmann visual fields (GVF) and visual acuities (VA) were assessed for 6\u201312 months after 7-day treatment, patients receiving consecutive oral doses (40\u2009mg\/m<jats:sup>2<\/jats:sup>) of 9-<jats:italic>cis-<\/jats:italic>retinyl acetate, a synthetic retinoid replacement.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Pathological effects of D477G variant were preliminarily assessed by electroretinography in mice expressing AAV-delivered D477G RPE65, by MTS [3-(4,5-dimethylthiazol-2-yl)\u22125-(3-carboxyme- thoxyphenyl)\u22122-(4-sulfophenyl)\u22122H-tetrazolium] assays on RPE viability and enzyme activity in cultured cells. In addition to a mild dominant effect reflected in reduced electroretinographics in mice, and reduced cellular function <jats:italic>in vitro<\/jats:italic>, D477G exhibited reduced enzymatic RPE65 activity <jats:italic>in vitro<\/jats:italic>. In patients, significant improvements were observed in GVF from baseline ranging from 70% to 200% in three of five subjects aged 67\u201368 years, with largest improvements at 7\u201310 months. Of two GVF non-responders, one had significant visual acuity improvement (5\u201315 letters) from baseline after 6 months.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Families with D477G variant have been identified in Ireland, the UK, France, the USA and Canada. Effects of single 7-day oral retinoid supplementation lasted at least 6\u2009months, possibly giving visual benefit throughout remaining life in patients with advanced disease, where gene therapy is unlikely to prove beneficial.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/bmjophth-2020-000462","type":"journal-article","created":{"date-parts":[[2020,5,5]],"date-time":"2020-05-05T13:42:17Z","timestamp":1588686137000},"page":"e000462","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":15,"title":["Advanced late-onset retinitis pigmentosa with dominant-acting D477G RPE65 mutation is responsive to oral synthetic retinoid therapy"],"prefix":"10.1136","volume":"5","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3964-4167","authenticated-orcid":false,"given":"Paul F","family":"Kenna","sequence":"first","affiliation":[{"name":"Institute of Genetics, University of Dublin, Trinity College, Dublin, Ireland"},{"name":"The Research Foundation, Royal Victoria Eye and Ear Hospital, Dublin, Ireland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marian M","family":"Humphries","sequence":"additional","affiliation":[{"name":"Institute of Genetics, University of Dublin, Trinity College, Dublin, Ireland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna-Sophia","family":"Kiang","sequence":"additional","affiliation":[{"name":"Institute of Genetics, University of Dublin, Trinity College, Dublin, Ireland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2739-1622","authenticated-orcid":false,"given":"Philippe","family":"Brabet","sequence":"additional","affiliation":[{"name":"Neurosciences, Institute for Neurosciences of Montpellier, Montpellier, Languedoc-Roussillon, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laurent","family":"Guillou","sequence":"additional","affiliation":[{"name":"Neurosciences, Institute for Neurosciences of Montpellier, Montpellier, Languedoc-Roussillon, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ema","family":"Ozaki","sequence":"additional","affiliation":[{"name":"Institute of Genetics, University of Dublin, Trinity College, Dublin, Ireland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew","family":"Campbell","sequence":"additional","affiliation":[{"name":"Institute of Genetics, University of Dublin, Trinity College, Dublin, Ireland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G Jane","family":"Farrar","sequence":"additional","affiliation":[{"name":"Institute of Genetics, University of Dublin, Trinity College, Dublin, Ireland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Koenekoop","sequence":"additional","affiliation":[{"name":"Departments of Ophthalmology, Human Genetics, and Paediatric Surgery, Montreal Children's Hospital, McGill University Health Centre, McGill University, Montreal, Quebec, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2928-5700","authenticated-orcid":false,"given":"Pete","family":"Humphries","sequence":"additional","affiliation":[{"name":"Institute of Genetics, University of Dublin, Trinity College, Dublin, Ireland"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2020,5,5]]},"reference":[{"key":"2025090110060739000_5.1.e000462.1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.AW118.003228"},{"key":"2025090110060739000_5.1.e000462.2","doi-asserted-by":"publisher","DOI":"10.1001\/archophthalmol.2010.210"},{"key":"2025090110060739000_5.1.e000462.3","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)60153-7"},{"key":"2025090110060739000_5.1.e000462.4","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0143846","article-title":"Safety and Proof-of-Concept Study of Oral QLT091001 in Retinitis Pigmentosa Due to Inherited Deficiencies of Retinal Pigment Epithelial 65 Protein (RPE65) or Lecithin:Retinol Acyltransferase (LRAT)","volume":"10","author":"Scholl","year":"2015","journal-title":"PLoS One"},{"key":"2025090110060739000_5.1.e000462.5","doi-asserted-by":"publisher","DOI":"10.1038\/ejhg.2011.86"},{"key":"2025090110060739000_5.1.e000462.6","doi-asserted-by":"publisher","DOI":"10.1080\/13816810.2018.1484929"},{"key":"2025090110060739000_5.1.e000462.7","first-page":"626","article-title":"The clinical features of retinal disease due to a dominant mutation in RPE65","volume":"22","author":"Hull","year":"2016","journal-title":"Mol Vis"},{"key":"2025090110060739000_5.1.e000462.8","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajpath.2016.11.004"},{"key":"2025090110060739000_5.1.e000462.9","doi-asserted-by":"publisher","DOI":"10.1093\/hmg\/ddy128"},{"key":"2025090110060739000_5.1.e000462.10","doi-asserted-by":"publisher","DOI":"10.1002\/humu.23706"},{"key":"2025090110060739000_5.1.e000462.11","doi-asserted-by":"crossref","first-page":"15016","DOI":"10.1038\/mtm.2015.16","article-title":"Efficient gene delivery to photoreceptors using AAV2\/rh10 and rescue of the Rho(-\/-) mouse","volume":"2","author":"Palfi","year":"2015","journal-title":"Mol Ther Methods Clin Dev"},{"key":"2025090110060739000_5.1.e000462.12","first-page":"95","article-title":"Conversion of planimetric visual field data into solid angles and retinal areas","volume":"5","author":"Dagnelie","year":"1990","journal-title":"Clin Vis Sci"},{"key":"2025090110060739000_5.1.e000462.13","doi-asserted-by":"publisher","DOI":"10.1001\/archopht.1993.01090060049022"},{"key":"2025090110060739000_5.1.e000462.14","doi-asserted-by":"publisher","DOI":"10.3727\/095535491820873191"},{"key":"2025090110060739000_5.1.e000462.15","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0064094","article-title":"Retinal pigmented epithelial cells cytotoxicity and apoptosis through activation of the mitochondrial intrinsic pathway: role of indocyanine green, brilliant blue and implications for chromovitrectomy","volume":"8","author":"Penha","year":"2013","journal-title":"PLoS One"},{"key":"2025090110060739000_5.1.e000462.16","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.11-8321"}],"container-title":["BMJ Open Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjophth-2020-000462","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T17:06:15Z","timestamp":1756746375000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjophth.bmj.com\/lookup\/doi\/10.1136\/bmjophth-2020-000462"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5]]},"references-count":16,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,5,5]]},"published-print":{"date-parts":[[2020,5]]}},"alternative-id":["10.1136\/bmjophth-2020-000462"],"URL":"https:\/\/doi.org\/10.1136\/bmjophth-2020-000462","relation":{},"ISSN":["2397-3269"],"issn-type":[{"value":"2397-3269","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,5]]}}}